These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 5804187)

  • 41. [Rubella immunity in Alsace. A study of 1026 serums by hemagglutination inhibition reaction].
    Wurtz R; Lab M; Kirn A
    Pathol Biol (Paris); 1970 Apr; 18(7):387-91. PubMed ID: 4911089
    [No Abstract]   [Full Text] [Related]  

  • 42. Antibody response in school children to live rubella vaccine (Cendehill strain).
    Iwakata S; Elkerton LE; Rhodes AJ; Bull JA; Labzoffsky NA
    Can Med Assoc J; 1972 May; 106(9):980-2. PubMed ID: 4554732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rubella vaccine trial in children.
    Hillary IB; Meenan PN; Griffith AH; Draper CC; Laurence GD
    Br Med J; 1969 May; 2(5656):531-2. PubMed ID: 5769885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement-fixing and fluorescent antibody responses to an attenuated Rubella virus vaccine.
    Schmidt NJ; Lennette EH
    Am J Epidemiol; 1970 Apr; 91(4):351-4. PubMed ID: 4912184
    [No Abstract]   [Full Text] [Related]  

  • 45. Experimental live attenuated rubella virus vaccine. Clinical evaluation of Cendehill strain.
    Prinzie A; Huygelen C; Gold J; Farquhar J; McKee J
    Am J Dis Child; 1969 Aug; 118(2):172-7. PubMed ID: 5794812
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical response to immunization with Cendehill strain rubella vaccine.
    Rogers KD; Ramirez G; Cortez M; Michaels R; Savin M; Montgomery R; Welty T; Taylor F; Hingson RA
    Pediatrics; 1971 Jan; 47(1):7-15. PubMed ID: 4250964
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical trial of live attenuated rubella virus vaccine, HPV-77 strain.
    Cooper LZ; Giles JP; Krugman S
    Am J Dis Child; 1968 Jun; 115(6):655-7. PubMed ID: 4968322
    [No Abstract]   [Full Text] [Related]  

  • 48. Combined live measles-rubella virus vaccine. Findings in clinical laboratory studies.
    Villarejos VM; Arguedas JA; Buynak EB; Weibel RE; Stokes J; Hilleman MR
    J Pediatr; 1971 Oct; 79(4):599-604. PubMed ID: 5094254
    [No Abstract]   [Full Text] [Related]  

  • 49. Genetic stability in humans of the rabbit immunogenic marker of Cendehill rubella vaccine virus.
    Gill SD; Furesz J
    Arch Gesamte Virusforsch; 1973; 43(1):135-43. PubMed ID: 4793528
    [No Abstract]   [Full Text] [Related]  

  • 50. [Characteristics of the reactogenic properties and effectiveness of live rubella vaccine].
    Iakovleva NV; Nasibov MN; Smorodintsev AA
    Vopr Virusol; 1969; 14(3):365-9. PubMed ID: 5820958
    [No Abstract]   [Full Text] [Related]  

  • 51. Present status of measles and rubella immunization in the United States: a medical progress report.
    Krugman S
    J Pediatr; 1971 Jan; 78(1):1-16. PubMed ID: 5539083
    [No Abstract]   [Full Text] [Related]  

  • 52. Herd immunity against Rubella virus in selected localities of Czechoslovakia.
    Strauss J
    Rev Czech Med; 1971; 17(2):49-56. PubMed ID: 5087468
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunogenicity and reactogenicity of live attenuated rubella virus vaccines.
    Andzhaparidze OG; Desyatskova RG; Chervonski GI; Pryanichnikova LV
    Am J Epidemiol; 1970 May; 91(5):527-30. PubMed ID: 5462118
    [No Abstract]   [Full Text] [Related]  

  • 54. [Level of antibodies against rubella in the normal population of Nanning city and a survey of the immunizing efficacy of rubella live-vaccines].
    Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Feb; 6(1):12-4. PubMed ID: 3995568
    [No Abstract]   [Full Text] [Related]  

  • 55. In vivo properties of attenuated rubella virus, "Cendehill" strain.
    Zygraich N; Peetermans J; Huygelen C
    Arch Gesamte Virusforsch; 1971; 33(3):225-33. PubMed ID: 5000190
    [No Abstract]   [Full Text] [Related]  

  • 56. Studies with rubella vaccine (RA 27-3) using the subcutaneous and intranasal routes.
    Moffat MA; Gould JJ; Forbes FA; Freestone DS; Macdonald A
    Scott Med J; 1972 Apr; 17(4):140-2. PubMed ID: 4554067
    [No Abstract]   [Full Text] [Related]  

  • 57. Response to experimental challenge in persons immunized with different rubella vaccines.
    Fogel A; Gerichter CB; Barnea B; Handsher R; Heeger E
    J Pediatr; 1978 Jan; 92(1):26-9. PubMed ID: 619075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccines to prevent rubella.
    André FE; Florent G; du Pan RM
    Lancet; 1980 Mar; 1(8169):657-8. PubMed ID: 6102664
    [No Abstract]   [Full Text] [Related]  

  • 59. [A comparative evaluation of the immunogenic activity of attenuated strains of rubella virus from the USA, Belgium and the USSR].
    Nifontova AI; Meshalova VN; Iakovleva NV; Smorodintsev AA
    Vopr Virusol; 1970; 15(6):711-4. PubMed ID: 5518646
    [No Abstract]   [Full Text] [Related]  

  • 60. [Problems of rubella prevention: vaccination of 51 fertile young women with the Wister Ra 27/3 virus strain].
    Russo F; Piro E; Frugiuele PL; Buffone E; Palma B; Greco LM
    Ann Sclavo; 1980; 22(1):57-62. PubMed ID: 7247485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.